Vident Investment Advisory’s Royalty Pharma RPRX Stock Holding History

Vident Investment Advisory’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,162	Closed	-$435K	–	1362
2022 Q1	$435K	Sell	11,162 -1,231	-10%	-$48.3K	0.01%	973
2021 Q4	$494K	Sell	12,393 -302	-2%	-$11.7K	0.01%	930
2021 Q3	$459K	Buy	+12,695	New	+$493K	0.01%	898
2021 Q1	–	Sell	-9,808	Closed	-$491K	–	1023
2020 Q4	$491K	Buy	+9,808	New	+$416K	0.02%	722

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Vident Investment Advisory's RPRX Position: Q2 2022 in Review

Vident Investment Advisory sold out of Royalty Pharma (RPRX) in Q2 2022, closing a stake of 11,162 shares — an estimated $435K sold.

Vident Investment Advisory first reported a position in RPRX in Q4 2020 and held it in 4 quarters. The position peaked at $494K in Q4 2021. 283 funds tracked by Wall St. Rank hold RPRX as of Q2 2022.

Vident Investment Advisory reported no remaining Royalty Pharma position as of Q2 2022 after selling out during the quarter.
Vident Investment Advisory sold 11,162 Royalty Pharma shares in Q2 2022, an estimated $435K.
Vident Investment Advisory first reported a position in Royalty Pharma in Q4 2020 and held it in 4 quarters.
Vident Investment Advisory's Royalty Pharma position peaked at $494K in Q4 2021.
283 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2022.

Based on Vident Investment Advisory's 13F filing for Q2 2022, filed 15 Aug 2022.